Trial results
$TSHA — TSHA-102
Taysha Gene Therapies, Inc. (TSHA) TSHA-102: trial results in Rett syndrome, 2027.
The catalyst
"Topline data from the REVEAL pivotal trial 6-month interim analysis and FDA feedback on the BLA submission pathway for TSHA-102 expected in the first half of 2027"
— Taysha Gene Therapies, Inc., 8-K filed 2026-11-12 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
TSHA-TSHA102-2026- Company
- Taysha Gene Therapies, Inc.
- Kind
- Trial results
- Indication
- Rett syndrome
- Window
- 2027-01-01 – 2027-06-30
- Status
- dropped
The bar
No bar has been published for this event yet.
Verdicts
No verdict has been published for this event yet.